<DOC>
	<DOC>NCT01063647</DOC>
	<brief_summary>Evaluation of the safety and efficacy of 3 x 10, 3 x 12 or 3 x 14 g/m² Treosulfan resp., combined with 5 x 30 mg/m² fludarabine prior to allogeneic, hematopoietic stem cell transplantation of patients with hematological malignancies, but non-eligible to standard conditioning treatment.</brief_summary>
	<brief_title>Dose-range Finding Treosulfan-based Conditioning</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Treosulfan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>1. Patients with a haematological chemosensitive malignancy indicated for an allogeneic transplantation, but presenting an increased toxicity risk for classical (highdose busulfan or standarddose total body irradiation) conditioning therapies (remission criteria ref. to Appendix L): CML in first or subsequent chronic phase NHL in 2nd CR/PR, chemosensitive PR after autologous transplantation ; CLL in 2nd or subsequent CR/PR Relapsed Morbus Hodgkin (MH) after autologous transplantation Multiple Myeloma (MM) stage II and III according to Durie and Salmon AML in 2nd CR/PR or highrisk AML in 1st CR/PR Highrisk defined for example by the following: Cytogenetics: 5/5q, 7/7q, del(5q), abnormalities of 3q, complex karyotype (&gt; 3 abnormalities), or PR after 1 cycle of induction therapy ALL in 2nd CR/PR or highrisk ALL in 1st CR/PR Highrisk defined as follows: Leukocytes &gt; 3000/µl (BLinage) or &gt; 100000/µl (TLinage); ProBALL, preTALL Cytogenetics: t(9;22)/BCRABL; t(4;11)/ALL1AF MDS (patients without prior chemotherapy may be included) 2. Availability of an HLAidentical sibling donor (MRD) or HLAidentical unrelated donor (MUD) or one mismatch (out of the 6 standard markers) sibling donor (1 misMRD): • HLAidentity defined by the following markers: A, B, DRB1. DQB1 must be recorded. 3. Age &gt; 18 years 4. Karnofsky Index &gt; 80 % 5. Adequate contraception in female patients of childbearing potential 6. Cooperative behavior of individual patients 7. Written informed consent 1. Completely chemotherapyresistant disease 2. Severe cardiac insufficiency, severe cardiovascular or other severe concomitant diseases 3. Symptomatic malignant involvement of the CNS 4. Active infectious disease 5. HIVpositive or active hepatitis infection 6. Impaired liver function (Bilirubin &gt; 1.5 x upper normal limit; Transaminases &gt; 3.0 x upper normal limit) 7. Impaired renal function (Creatinineclearance &lt; 60 ml/min; Serum Creatinine &gt; 1.5 x upper normal limit). 8. Pleural effusion or ascites &gt; 1.0 L 9. Pregnancy or lactation 10. Known hypersensitivity to fludarabine and/or treosulfan 11. Parallel participation in another experimental drug trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Treosulfan</keyword>
	<keyword>Allogeneic stem cell transplantation</keyword>
	<keyword>Conditioning therapy</keyword>
</DOC>